Ibio (IBIO) AI Stock Analysis

• Market Cap: $26.13M
• Dividend Yield: N/A
• Average Volume (3M): 5.75M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: 77.78%
• EPS Growth: 84.08%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 20,254,599
• 10 Day Avg. Volume: 3,747,766
• 30 Day Avg. Volume: 5,749,966
• PEG Ratio: <0.01
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 20.03
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $3.90
• Price Target Upside: 212.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.00 ▼(-20.00% Downside)

Ibio's overall stock score is primarily impacted by its poor financial performance, characterized by persistent losses and negative cash flows. While technical analysis provides some positive signals, the negative valuation metrics further weigh down the score. The lack of earnings call and corporate events data limits additional insights.

Ibio Business Overview & Revenue Model

Company Description

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

How the Company Makes Money

Ibio generates revenue through a combination of product sales, research and development collaborations, and licensing agreements. The company partners with other biotech firms and academic institutions to co-develop its products, sharing in the financial benefits of successful outcomes. Additionally, Ibio may receive upfront payments, milestone payments, and royalties from its partners based on the sales of products developed using its technology. The revenue model is further supported by grants and contracts, particularly for vaccine development and other projects that align with public health initiatives.

Ibio Financial Statement Overview

Summary

Ibio's financial health is challenged by consistent losses and declining revenue, despite some improvement in leverage ratios. Cash flow issues persist, requiring external funding to maintain operations. The company faces significant risks due to its high operational inefficiencies and ongoing cash burn.

Income Statement

The company shows a declining trend in revenue, with significant losses in net income and EBIT. The TTM Gross Profit Margin is inflated due to the inclusion of other income streams, but the core revenue remains weak. The negative EBIT and EBITDA margins indicate operational inefficiency and high expenses relative to revenue.

Balance Sheet

The company's debt-to-equity ratio has improved, indicating better leverage management, but overall equity is decreasing. The equity ratio shows a decline in shareholders' equity as a proportion of total assets, suggesting potential risk. Despite these issues, the company has managed to reduce liabilities over time.

Cash Flow

Operating cash flow remains negative, reflecting ongoing cash burn, though financing activities have temporarily supported liquidity. The free cash flow to net income ratio is unfavorable, highlighting unsustainable operations without external financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	400.00K	400.00K	225.00K	0.00	1.88M	2.37M
Gross Profit	400.00K	400.00K	225.00K	-1.11M	2.17M	909.00K
EBITDA	-17.04M	-17.04M	-14.02M	-28.12M	-25.72M	-18.34M
Net Income	-18.38M	-18.38M	-24.91M	-29.31M	-51.01M	-23.21M
Balance Sheet
Total Assets	23.18M	23.18M	28.73M	41.21M	99.41M	146.97M
Cash, Cash Equivalents and Short-Term Investments	8.58M	8.58M	14.21M	4.30M	33.52M	96.97M
Total Debt	3.51M	3.51M	4.46M	17.07M	25.77M	32.72M
Total Liabilities	8.30M	8.30M	7.41M	25.83M	35.92M	38.40M
Stockholders Equity	14.88M	14.88M	21.32M	15.38M	63.48M	108.58M
Cash Flow
Free Cash Flow	-15.32M	-15.32M	-18.76M	-36.17M	-49.11M	-35.23M
Operating Cash Flow	-15.30M	-15.30M	-18.55M	-30.44M	-37.48M	-30.06M
Investing Cash Flow	742.00K	742.00K	906.00K	7.01M	-5.13M	-26.48M
Financing Cash Flow	8.93M	8.93M	24.49M	2.30M	-6.13M	78.83M

Ibio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Negative. The current price of 1.25 is below the 20-day moving average (MA) of 1.31, above the 50-day MA of 1.03, and below the 200-day MA of 1.69, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 51.14 is Neutral, neither overbought nor oversold. The STOCH value of 12.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IBIO.

Ibio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PULM	53 Neutral	$17.64M	―	-79.47%	―	-99.97%	35.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IBIO	45 Neutral	$26.13M	―	-101.52%	―	77.78%	84.08%
FBLG	38 Underperform	$16.83M	-0.68	-1292.87%	―	―	18.47%
NERV	34 Underperform	$25.67M	2.47	―	―	―	-323.61%
CMMB	33 Underperform	$13.81M	-1.09	-120.76%	―	―	47.86%

Ibio Corporate Events

iBio Regains Nasdaq Compliance with Bid Price Rule

On November 4, 2025, iBio, Inc. announced that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. This follows a previous notification on July 29, 2025, indicating non-compliance due to the company’s stock price falling below the required threshold between June 13, 2025, and July 28, 2025. The issue is now resolved, closing the matter.

The most recent analyst rating on (IBIO) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

iBio Unveils Promising Preclinical Data for IBIO-610

On October 30, 2025, iBio, Inc. announced new preclinical data from its study on IBIO-610, an Activin E antibody candidate, showing an extended half-life of 33.2 days in obese non-human primates. This data, to be presented at ObesityWeek 2025, predicts a human half-life of up to 100 days, potentially allowing for twice-yearly dosing, which could significantly enhance patient experience and position IBIO-610 as a leading therapy for obesity and cardiometabolic diseases.

The most recent analyst rating on (IBIO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

Ibio Inc’s Future at Risk: Reliance on Third-Party Licenses for Key Product Candidates

Ibio Inc faces significant business risks due to its reliance on intellectual property licensed from third parties, particularly concerning its advanced product candidates, IBIO-600 and IBIO-610. These dependencies are tied to exclusive agreements with AstralBio, which grant Ibio Inc the rights to develop and commercialize these candidates. The termination of these licenses could lead to the loss of critical rights, adversely affecting the company’s ability to bring these products to market. Additionally, disputes over intellectual property or failure by licensors to enforce patents could further jeopardize Ibio Inc’s operations and financial health.

iBio, Inc. Reports Transformative Fiscal Year 2025

iBio, Inc. is a biotechnology company that leverages artificial intelligence and advanced computational biology to develop precision antibody therapies for cardiometabolic diseases, obesity, cancer, and other hard-to-treat conditions.

iBio Announces $50 Million Public Offering Agreement

On August 19, 2025, iBio, Inc. announced an underwriting agreement with Leerink Partners LLC for a public offering involving pre-funded warrants and Series G and H warrants to purchase shares of common stock. The offering, expected to raise approximately $50 million, aims to advance iBio’s preclinical cardiometabolic programs and other pipeline assets. The company has agreed to certain restrictions on stock issuance and sale for 90 days following the offering’s pricing. The offering’s completion is subject to customary closing conditions, with the closing expected around August 22, 2025.

The most recent analyst rating on (IBIO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

iBio Highlights Advancements in Obesity Pipeline

On August 18, 2025, iBio updated its corporate presentation to highlight advancements in its obesity and cardiometabolic diseases pipeline, focusing on the development of precision antibodies. The company has made significant progress with its preclinical candidates, IBIO-610 and IBIO-600, which have shown promising results in preclinical studies for inducing fat-selective weight loss and preserving muscle mass. iBio’s strategy involves leveraging AI to rapidly develop biologics and seeking strategic partnerships to advance its programs toward clinical trials. The announcement underscores iBio’s commitment to redefining obesity care and its potential impact on the industry by addressing unmet needs in current therapies.

The most recent analyst rating on (IBIO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.